What is William Blair’s Forecast for Amgen FY2025 Earnings?

Amgen Inc. (NASDAQ:AMGN) – William Blair lifted their FY2025 earnings estimates for shares of Amgen in a research note issued on Friday, October 10th. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings of $20.90 per share for the year, up from their prior forecast of $20.86. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter last year, the business posted $4.97 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

A number of other equities research analysts also recently weighed in on AMGN. Morgan Stanley raised their target price on shares of Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup raised their price objective on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $305.00 target price on shares of Amgen in a research note on Tuesday, June 24th. Finally, Bank of America raised their price target on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $309.42.

Amgen Stock Performance

Shares of AMGN opened at $292.40 on Monday. Amgen has a 12-month low of $253.30 and a 12-month high of $335.88. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The company has a market cap of $157.42 billion, a PE ratio of 23.91, a price-to-earnings-growth ratio of 2.52 and a beta of 0.49. The stock has a 50-day moving average price of $286.58 and a 200-day moving average price of $287.33.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. First Bank & Trust grew its holdings in Amgen by 10.3% in the 3rd quarter. First Bank & Trust now owns 12,417 shares of the medical research company’s stock worth $3,504,000 after acquiring an additional 1,155 shares during the last quarter. Arlington Financial Advisors LLC boosted its holdings in shares of Amgen by 1.9% during the third quarter. Arlington Financial Advisors LLC now owns 25,355 shares of the medical research company’s stock worth $7,155,000 after purchasing an additional 471 shares during the period. Lineweaver Wealth Advisors LLC grew its stake in shares of Amgen by 13.0% in the third quarter. Lineweaver Wealth Advisors LLC now owns 7,153 shares of the medical research company’s stock worth $2,019,000 after purchasing an additional 822 shares during the last quarter. Charles Schwab Trust Co increased its holdings in Amgen by 32.9% during the 3rd quarter. Charles Schwab Trust Co now owns 1,571 shares of the medical research company’s stock valued at $443,000 after purchasing an additional 389 shares during the period. Finally, Thomasville National Bank raised its position in Amgen by 11.2% during the 3rd quarter. Thomasville National Bank now owns 2,870 shares of the medical research company’s stock valued at $810,000 after purchasing an additional 290 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.